Nevertheless, PPARγ is still one of the most important targets for the treatment of insulin resistance and type 2 diabetes, and novel strategies to modulate PPARγ activity to enhance its beneficial effects and reduce unwanted adverse effects are strongly anticipated. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.